The UIC team used protein engineering to design “a new biologic compound that tries to maximize the therapeutic effects of the enzyme while reducing toxicity and harmful responses in the patient,” according to a Jan. 28 news release from the university.
The compound destroyed leukemia cells in mice and shrank melanoma and liver cancer tumors in laboratory models, the release said. The group hopes to bring the compound to clinical trials.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
